Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
IPO Year: 2020
Exchange: NASDAQ
Website: accolade.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2024 | $13.00 → $8.00 | Buy | Needham |
| 2/26/2024 | $16.00 | Outperform | Leerink Partners |
| 1/17/2024 | $16.00 → $14.00 | Neutral | DA Davidson |
| 1/3/2024 | $13.00 | Equal Weight | Barclays |
| 5/24/2023 | $16.50 | Neutral → Buy | BofA Securities |
| 4/12/2023 | $18.00 | Overweight | Stephens |
| 3/23/2023 | $16.00 | Neutral → Buy | Guggenheim |
| 2/9/2023 | $14.00 | Buy → Hold | Jefferies |
| 2/2/2023 | $15.00 | Outperform | Raymond James |
| 9/8/2022 | $12.00 | Overweight | Piper Sandler |
15-12G - Accolade, Inc. (0001481646) (Filer)
SCHEDULE 13D/A - Accolade, Inc. (0001481646) (Subject)
25-NSE - Accolade, Inc. (0001481646) (Subject)
S-8 POS - Accolade, Inc. (0001481646) (Filer)
S-8 POS - Accolade, Inc. (0001481646) (Filer)
S-8 POS - Accolade, Inc. (0001481646) (Filer)
S-8 POS - Accolade, Inc. (0001481646) (Filer)
S-8 POS - Accolade, Inc. (0001481646) (Filer)
8-K - Accolade, Inc. (0001481646) (Filer)
144 - Accolade, Inc. (0001481646) (Subject)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
Fastest customizable press release news feed in the world
Creating the Most Comprehensive Health and Care Platform for Employers and Health Plans Serving 20 Million Members & 1,700 Employer and Health Plan Clients Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual primary care company in the market. The combined organization now serves over 20 million Members and more than 1,700 employer and health plan clients as the One Place for Health and Care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407811112/en/ With the completion of the transaction, Transcarent will offer a health and car
SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the "Special Meeting") held earlier today. The final, certified voting results for the Special Meeting will be provided in a Form 8-K filed with the U.S. Securities and Exchange Commission. The transaction remains on track to be completed in the second quarter of calendar year 2025 and is subject to customary closing conditions, including the receipt of certain state regulatory approvals. Upon completion of the transaction, Accolade will become a privately held company and shares of Accol
Partnership increases access to specialized, whole-person clinical care for people managing digestive health conditions SEATTLE, March 6, 2025 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD) has partnered with Oshi Health, a leading virtual clinic specializing in gastrointestinal (GI) conditions that delivers convenient, accessible, whole-person care through a collaborative, multidisciplinary approach. This partnership adds to Accolade's existing GI health partnership with Cylinder and reinforces Accolade's commitment to delivering best-in-class health solutions to customers and their employee and member populations.
SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the waiting period under the Hart-Scott-Rodino ("HSR") Antitrust Improvements Act of 1976 with respect to the previously announced merger between the two companies. The transaction remains on track to be completed in the second quarter of calendar year 2025, subject to Accolade stockholder approval and satisfaction of other customary closing conditions. Glen Tullman, Chief Executive Officer of Transcarent, said, "With this milestone behind us, we ar
Effort broadens healthcare access and removes barriers to primary care and weight management services SEATTLE, Feb. 4, 2025 /PRNewswire/ -- Today, Accolade, Inc. (NASDAQ:ACCD) announced that its direct-to-consumer virtual healthcare offering, PlushCare, is now accepting Medicare Part B, expanding care access to 64 million beneficiaries across all 50 states. PlushCare offers quality primary care, clinical weight management services, and mental health support from leading providers. This expansion enhances accessibility and convenience for older adults and younger individuals with disabilities or chronic conditions, empowering them to manage their health better and improve their quality of lif
Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment Transcarent's Generative AI WayFinding and care experiences combined with Accolade's Advocacy, Expert Medical Opinion, and Primary Care will deliver on the promise of ‘One Place for Health and Care' Accolade shareholders to receive $7.03 per share in cash SAN FRANCISCO and SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent wil
SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/register/BI0dce2f02ed2f44c8901127623aa788c3) Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a li
SEATTLE, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will be presenting at the following upcoming investor events. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. Stephens Annual Investment Conference | NASH2024 in Nashville on Wednesday, November 20 at 9:00 am CTCG MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21. (1x1 meetings, no webcast)Piper Sandler 36th Annual Healthcare Conference in New York on Thursday, December 5 at 10:00 am ET. About Accolade, Inc. Accolade (NASDAQ:ACCD) is a Personalized Healthcare company that provides millions of people and the
Partnership will drive cost savings for customers while providing high-touch services that improve health outcomes to members with chronic kidney disease (CKD). SEATTLE, Oct. 15, 2024 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD) today announced that Renalogic, the recognized industry leader that manages the human and financial costs of chronic kidney disease (CKD) for self-insured employers and their members, will join the company's Trusted Partner Ecosystem, to offer its proven CKD risk management and dialysis cost containment solutions. Employers' health costs are expected
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Needham reiterated coverage of Accolade with a rating of Buy and set a new price target of $8.00 from $13.00 previously
Leerink Partners initiated coverage of Accolade with a rating of Outperform and set a new price target of $16.00
DA Davidson resumed coverage of Accolade with a rating of Neutral and set a new price target of $14.00 from $16.00 previously
Barclays initiated coverage of Accolade with a rating of Equal Weight and set a new price target of $13.00
BofA Securities upgraded Accolade from Neutral to Buy and set a new price target of $16.50
Stephens initiated coverage of Accolade with a rating of Overweight and set a new price target of $18.00
Guggenheim upgraded Accolade from Neutral to Buy and set a new price target of $16.00
Jefferies downgraded Accolade from Buy to Hold and set a new price target of $14.00
Raymond James initiated coverage of Accolade with a rating of Outperform and set a new price target of $15.00
Piper Sandler resumed coverage of Accolade with a rating of Overweight and set a new price target of $12.00
This live feed shows all institutional transactions in real time.
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
Live Leadership Updates
SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the waiting period under the Hart-Scott-Rodino ("HSR") Antitrust Improvements Act of 1976 with respect to the previously announced merger between the two companies. The transaction remains on track to be completed in the second quarter of calendar year 2025, subject to Accolade stockholder approval and satisfaction of other customary closing conditions. Glen Tullman, Chief Executive Officer of Transcarent, said, "With this milestone behind us, we ar
Welcomes Dr. Connie Hwang as chief medical officer, creates roles of chief health officer and chief nursing officer SEATTLE, Sept. 18, 2023 /PRNewswire/ -- Accolade (NASDAQ:ACCD) announced the expansion of its care delivery team, strengthening the company's ability to streamline healthcare experiences through physician-led advocacy. Connie Hwang, MD, MPH, joins Accolade to lead population health strategies for employers and health plans. Led by Shantanu Nundy, MD, executive vice president, chief health officer, the care delivery leadership team includes Dr. Hwang, senior vice president, chief medical officer; James Wantuck, MD, senior vice president, associate chief medical officer and co-fo
With the addition of senior vice president and CISO, Kelli Burns, Accolade further elevates its focus on trusted, personalized relationships through exceptional information security for its members and customers SEATTLE, July 25, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today that Kelli Burns has joined the organization as senior vice president, chief information security officer. Burns, a former consultant with Ernst & Young LLP (EY US) focused on cybersecurity en
Accolade welcomes executive vice president and chief human resources officer Jennifer Hanson to create an amazing employee experience for the company that partners with human resource leaders to deliver Personalized Healthcare SEATTLE, May 2, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with exceptional healthcare, announced today the appointment of Jennifer Hanson as chief human resources officer, executive vice president of people and culture, reporting to Accolade CEO, Rajeev Singh. Hanson will oversee
Live finance-specific insights
Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment Transcarent's Generative AI WayFinding and care experiences combined with Accolade's Advocacy, Expert Medical Opinion, and Primary Care will deliver on the promise of ‘One Place for Health and Care' Accolade shareholders to receive $7.03 per share in cash SAN FRANCISCO and SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent wil
SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/register/BI0dce2f02ed2f44c8901127623aa788c3) Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a li
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s
SEATTLE, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal second quarter 2025 financial results on Tuesday, October 8, 2024 before market open. In conjunction, the company will host a conference call to review results at 8:00 a.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI0b6b999c6e7b47fdb26d7e8a774df09f). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a live a
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal first quarter 2025 financial results on Thursday, June 27, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI651ad6356ede4b179553cca22ec02b2f). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via
SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal fourth quarter and full year ended February 29, 2024. "Accolade has built a rare healthcare services business at scale with consistently strong growth rates. Whether serving consumers, employers, health plans, or government entities, the core of our value proposition is making healthcare easier to access, navigate, and consume for our members. We provide a unique blend of healthcare services and next generation technology that will further differentiate us in FY 2025 as we approach $500 million in revenues and forecast full year positive Adjusted EBITDA," said Rajeev S
SEATTLE, April 03, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal fourth quarter 2024 financial results on Thursday, April 25, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/register/BI5dc020b8e7534a2ab2036759667cf1a2) Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be acc
SEATTLE, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal third quarter ended November 30, 2023. "As we head into the new year, Accolade continues to define the future of how healthcare should be experienced in this country. Our unique combination of people and technology is creating a new model for improving health outcomes and helping our more than 10 million members live healthier lives. We are closing the physician gap, improving access to care, and leveraging AI and other innovations to make the system work better for our employer customers, their employees and their families. The results can be seen in our growing custom
SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal third quarter 2024 financial results on Monday, January 8, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI0aea659c422c4c259198c9c7e6313d1b). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via
SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2023. "We are halfway through the 2024 fiscal year and the demand environment for our solutions remains strong. Accolade continues to lay the foundation to build a lasting, scalable business that will improve people's lives and fundamentally change the way healthcare is experienced in this country. Accolade's unique combination of advocacy and care solutions is changing the way employers deliver healthcare to their employees and their families, and the success of this strategy is evident in our growing customer base which now totals more